Skip to main content
Clinical Trials/CTRI/2021/08/035409
CTRI/2021/08/035409
Completed
Phase 1

Bubble Continuous Positive Airway Pressure Oxygen Therapy (Biodesign Innovation Labsâ??s RESPAP KIT )in Children under Five Years of Age with Pneumonia in Pediatric Intensive Care Unit (PICU)-A Pilot study - B-CPAP

Biodesign Innovation Labss RESPAP KIT0 sites30 target enrollmentTBD

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Health Condition 1: J159- Unspecified bacterial pneumonia
Sponsor
Biodesign Innovation Labss RESPAP KIT
Enrollment
30
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
November 8, 2021
Last Updated
3 years ago
Study Type
Interventional

Investigators

Sponsor
Biodesign Innovation Labss RESPAP KIT

Eligibility Criteria

Inclusion Criteria

  • 1\)Children aged 5\-59 months with diagnosis of pneumonia with mild to moderate respiratory distress

Exclusion Criteria

  • 1\)Those patients who required immediate intubation ( \<1hour),
  • 2\) low level of consciousness (GCS \<10\)
  • 3\)less than 24 hours of stay in PICU,
  • 4\) absent cough/ gag reflex,
  • 5\) hemodynamic instability
  • 6\)recent facial, upper airway or upper gastrointestinal tract surgery,
  • 7\)undrained pneumothorax
  • 8\)Hypercapnia (PCO2 \> 60 mm of Hg),

Outcomes

Primary Outcomes

Not specified

Similar Trials